In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics, with a price target of $8.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
John Newman’s rating is based on several promising developments for Marker Therapeutics. The company anticipates a significant data update for their MT-601 therapy in the latter half of 2025, which is expected to include a larger patient sample. This therapy targets relapsed lymphoma patients using a unique multi-antigen approach, setting it apart from existing CD19 CAR-T therapies.
Marker Therapeutics sees a substantial commercial opportunity in the lymphoma market, estimating around 8,000 patients globally by 2024, with a significant portion experiencing relapse. The potential market size is projected to be approximately $1.7 billion. The company’s financial position, with $13.7 million in cash reported in the first quarter of 2025, supports their ongoing research and development efforts, justifying the Buy rating and an $8 price target.
MRKR’s price has also changed moderately for the past six months – from $1.590 to $1.280, which is a -19.50% drop .